share_log

ResMed Insiders Sold US$9.2m Of Shares Suggesting Hesitancy

ResMed Insiders Sold US$9.2m Of Shares Suggesting Hesitancy

瑞思邁內部人士出售了920萬美元的股票,這表明他們猶豫不決
Simply Wall St ·  03/10 10:45

Many ResMed Inc. (NYSE:RMD) insiders ditched their stock over the past year, which may be of interest to the company's shareholders. When evaluating insider transactions, knowing whether insiders are buying versus if they selling is usually more beneficial, as the latter can be open to many interpretations. However, shareholders should take a deeper look if several insiders are selling stock over a specific time period.

在過去的一年中,許多瑞思邁公司(紐約證券交易所代碼:RMD)內部人士拋售了股票,這可能會引起該公司的股東的興趣。在評估內幕交易時,了解內部人士是買入還是賣出通常更有利,因爲後者可能有多種解釋。但是,股東應更深入地研究是否有幾位內部人士在特定時間段內出售股票。

While insider transactions are not the most important thing when it comes to long-term investing, logic dictates you should pay some attention to whether insiders are buying or selling shares.

儘管在長期投資中,內幕交易並不是最重要的事情,但邏輯要求你應該注意內部人士是在買入還是賣出股票。

ResMed Insider Transactions Over The Last Year

瑞思邁去年的內幕交易

The Founder, Peter Farrell, made the biggest insider sale in the last 12 months. That single transaction was for US$5.0m worth of shares at a price of US$237 each. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. The silver lining is that this sell-down took place above the latest price (US$188). So it is hard to draw any strong conclusion from it.

創始人彼得·法雷爾進行了過去12個月中最大規模的內幕出售。這筆單筆交易是價值500萬美元的股票,每股價格爲237美元。儘管內幕拋售是負面的,但對我們來說,如果以較低的價格出售股票,則負面影響更大。一線希望是,這種拋售發生在最新價格(188美元)之上。因此,很難從中得出任何強有力的結論。

ResMed insiders didn't buy any shares over the last year. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

瑞思邁內部人士去年沒有購買任何股票。您可以看到下圖所示的去年的內幕交易(公司和個人)。如果你點擊圖表,你可以看到所有的個人交易,包括股價、個人和日期!

insider-trading-volume
NYSE:RMD Insider Trading Volume March 10th 2024
紐約證券交易所:RMD 內幕交易量 2024 年 3 月 10 日

I will like ResMed better if I see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.

如果我看到一些重大的內幕收購,我會更喜歡瑞思邁的。在我們等待的同時,請查看這份免費清單,列出了最近有大量內幕收購的成長型公司。

Insiders At ResMed Have Sold Stock Recently

瑞思邁的內部人士最近出售了股票

Over the last three months, we've seen significant insider selling at ResMed. In total, Founder Peter Farrell dumped US$5.0m worth of shares in that time, and we didn't record any purchases whatsoever. This may suggest that some insiders think that the shares are not cheap.

在過去的三個月中,我們看到了瑞思邁的大量內幕拋售。創始人彼得·法雷爾當時總共拋售了價值500萬美元的股票,我們沒有記錄任何購買記錄。這可能表明一些內部人士認爲股票並不便宜。

Does ResMed Boast High Insider Ownership?

瑞思邁是否擁有很高的內部所有權?

Many investors like to check how much of a company is owned by insiders. We usually like to see fairly high levels of insider ownership. ResMed insiders own 0.9% of the company, currently worth about US$242m based on the recent share price. Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.

許多投資者喜歡查看公司內部人士擁有多少股份。我們通常希望看到相當高的內部所有權水平。瑞思邁內部人士擁有該公司0.9%的股份,根據最近的股價,目前價值約2.42億美元。大多數股東會很高興看到這種內部所有權,因爲這表明管理層的激勵措施與其他股東非常一致。

What Might The Insider Transactions At ResMed Tell Us?

瑞思邁的內幕交易能告訴我們什麼?

An insider sold ResMed shares recently, but they didn't buy any. And even if we look at the last year, we didn't see any purchases. But it is good to see that ResMed is growing earnings. It is good to see high insider ownership, but the insider selling leaves us cautious. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. To assist with this, we've discovered 1 warning sign that you should run your eye over to get a better picture of ResMed.

一位內部人士最近出售了瑞思邁的股票,但他們沒有購買任何股票。而且,即使我們看看去年,我們也沒有看到任何購買。但很高興看到瑞思邁的收益正在增長。看到較高的內部所有權是件好事,但內幕拋售使我們持謹慎態度。雖然我們喜歡了解內部人士的所有權和交易情況,但在做出任何投資決策之前,我們一定要考慮股票面臨的風險。爲了幫助解決這個問題,我們發現了一個警告信號,你應該仔細看看,以便更好地了解瑞思邁的情況。

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

當然,通過尋找其他地方,你可能會找到一筆不錯的投資。因此,來看看這份有趣的公司的免費清單吧。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

就本文而言,內部人士是指向相關監管機構報告其交易的個人。我們目前只考慮公開市場交易和私下處置的直接利益,不包括衍生品交易或間接權益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論